Helixmith's 'Enzensus' Fails Phase 3 Clinical Trial for Diabetic Neuropathy
Helixmith's core pipeline, 'Engensis (VM202),' failed to meet the primary endpoint in its Phase 3 clinical trial.
Helixmith announced on the 3rd that the analysis of the top-line data from the Phase 3-2 and 3-2b clinical trials of Engensis targeting diabetic peripheral neuropathy (DPN) conducted in the United States failed to achieve the primary endpoint.
This clinical trial compared the average daily pain score (ADPS) over the past week at 6 months (180 days) and 12 months (365 days) after the first dose between the Engensis group and the placebo group. The Phase 3-2 trial involved 162 patients, and the Phase 3-2b trial was conducted on 106 patients who agreed to participate in the extension study.
However, in this trial, patients who received Engensis did not demonstrate a statistically significant reduction in average pain compared to those who received the placebo. The company stated, "Further analyses on secondary endpoints, exploratory endpoints, and subgroups will continue."
Currently, Engensis is also undergoing clinical trials for diabetic foot ulcers, another diabetic complication, and the company plans to prioritize development in this area. A Phase 3 clinical trial for critical limb ischemia (CLI), a severe form of diabetic foot ulcer, is underway through its Chinese partner, Northland Biotech. The clinical results are expected to be announced within this year.
Sunyoung Kim, Chief Strategy Officer (CSO) and Founder of Helixmith
Photo by Chunhee Lee
Sunyoung Kim, founder and Chief Strategy Officer (CSO) of Helixmith, said, "We are deeply disappointed to receive such results in the disease area that was the most advanced. Once the Phase 3 results for the second target disease, diabetic foot ulcers, are available, we will compile all clinical results and report them to the new management team, which will determine the development direction and investment priorities for Engensis."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jiwook Jung, Vice President of Biosolution, which recently became Helixmith's largest shareholder through a third-party allotment capital increase, stated, "The success of the Engensis DPN clinical trial was not a consideration in Biosolution's investment in Helixmith. The primary purpose of the investment is to utilize the know-how and intellectual property accumulated by Helixmith through various projects as a platform." He added, "With this result, the fixed image of ‘Helixmith = Engensis DPN’ has disappeared, removing uncertainties about the company. We believe that the improved financial structure provides an opportunity to expand and develop other businesses."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.